Vasculitis induced by immunization with Bacillus Calmette-Guérin followed by atypical mycobacterium antigen: A new mouse model for Kawasaki disease

FEMS Immunology and Medical Microbiology

Volumn 49, Issue 3, 2007, Pages 391-397

  Nakamura, Tsuneyuki ^a,b   Yamamura, Jun Ichi ^a   Sato, Hitoshi ^a   Kakinuma, Hiroaki ^a   Takahashi, Hiroaki ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b NONE   (Japan)

Author keywords

Atypical mycobacterium; BCG; Kawasaki disease; Mouse model; Peroxiredoxin

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOBACTERIUM ANTIGEN; PEROXIREDOXIN; PEROXIREDOXIN 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERITIS; ARTICLE; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; AUTOIMMUNITY; BACILLUS; BLOOD VESSEL WALL; CELL INFILTRATION; CONTROL GROUP; CONTROLLED STUDY; CORONARY ARTERY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPATHOLOGY; INFLAMMATORY CELL; INOCULATION; MICROORGANISM; MOUSE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYCOBACTERIUM INTRACELLULARE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTIGENS, BACTERIAL; AUTOANTIBODIES; AUTOIMMUNITY; CHEMOKINE CCL2; CORONARY VESSELS; DISEASE MODELS, ANIMAL; FEMALE; HISTOCYTOCHEMISTRY; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM BOVIS; PEROXIDASES; TUMOR NECROSIS FACTOR-ALPHA; VASCULITIS;

EID: 33947279513     PISSN: 09288244     EISSN: 1574695X     Source Type: Journal    
DOI: 10.1111/j.1574-695X.2007.00217.x     Document Type: Article

References (44)

1. Abe J, Onimaru M, Matsumoto S, Noma S, Baba K, Ito Y, Kohsaka T & Takeda T (1997) Clinical role for a superantigen in Yersinia pseudotuberculosis infection. J Clin Invest 99: 1823-1830.
2. Akiyama T & Yashiro K (1993) Probable role of Streptococcus pyogenes in Kawasaki disease. Eur J Pediatr 152: 82-92.
3. Asano T & Ogawa S (2000) Expression of IL-8 in Kawasaki disease. Clin Exp Immunol 122: 514-519.
4. Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura Y, Kiyosawa N, Ishii M & Harada K (2005) Kawasaki Disease Research Committee. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int 47: 232-234.
5. Belizna C & Tervaert JW (1997) Specificity, pathogenecity, and clinical value of antiendothelial cell antibodies. Semin Arthritis Rheum 27: 98-109.
6. Bosch X, Guilabert A & Font J (2006) Antineutrophil cytoplasmic antibodies. Lancet 368: 404-418.
7. Burns JC & Glode MP (2004) Kawasaki syndrome. Lancet 364: 533-544.
8. Choi MH, Lee IK, Kim GW et al. (2005) Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II. Nature 435: 347-353.
9. Eberhard BA, Andersson U, Laxer RM, Rose R & Silverman ED (1995) Evaluation of the cytokine response in Kawasaki disease. Pediatr Infect Dis J 14: 199-203.
10. Esper F, Shapiro ED, Weibel C, Ferguson D, Landry ML & Kahn JS (2005) Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 191: 499-502.
11. Fukazawa R, Sonobe T, Hamamoto K et al. (2004) Possible synergic effect of angiotensin-I converting enzyme gene insertion/deletion polymorphism and angiotensin-II type-1 receptor 1166A/C gene polymorphism on ischemic heart disease in patients with Kawasaki disease. Pediatr Res 56: 597-601.
12. Furukawa S, Matsubara T, Jujoh K, Yone K, Sugawara T, Sasai K, Kato H & Yabuta K (1988) Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease. Clin Immunol Immunopathol 48: 247-251.
13. Gasior-Chrzan B (2001) Delayed granulomatous lesion at the bacillus Calmette-Guerin vaccination site. Acta Derm Venereol 81: 302-304.
14. Harlow E & Lane D (1988) Antibodies: a Laboratory Manual. Cold Spring Harbor Laboratory Press, NY.
15. Hofmann B, Hecht HJ & Flohe L (2002) Peroxiredoxins. Biol Chem 383: 347-364.
16. Ihira M, Yoshikawa T, Ishii J et al. (2002) Serological examination of human herpesvirus 6 and 7 in patients with coronary artery disease. J Med Virol 67: 534-537.
17. Kaneko K, Savage CO, Pottinger BE, Shah V, Pearson JD & Dillon MJ (1994) Antiendothelial cell antibodies can be cytotoxic to endothelial cells without cytokine pre-stimulation and correlate with ELISA antibody measurement in Kawasaki disease. Clin Exp Immunol 98: 264-269.
18. Karasawa R, Sekine T, Oota S et al. (2003) Targets of anti-endothelial cell antibodies in patients with systemic vasculitis: identification by the proteomic approach. Arthritis Rheum 48 (Suppl), 391.
19. Kariyazono H, Ohno T, Khajoee V, Ihara K, Kusuhara K, Kinukawa N, Mizuno Y & Hara T (2004) Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease. Pediatr Res 56: 953-959.
20. Kawasaki T (1967) Pediatric acute mucocutaneous lymph node syndrome: clinical observation of 50 cases. Arerugi (Jpn J Allergy) 16: 178-222.
21. Kawasaki T, Kosaki F, Okawa S, Shigematsu I & Yanagawa H (1974) A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 54: 271-276.
22. Kikuta H, Taguchi Y, Tomizawa K et al. (1988) Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease. Nature 333: 455-457.
23. Kuniyuki S & Asada M (1997) An ulcerated lesion at the BCG vaccination site during the course of Kawasaki disease. J Am Acad Dermatol 37: 303-304.
24. Lee SC, Na YP & Lee JB (2003) Expression of peroxiredoxin II in vascular tumors of the skin: a novel vascular marker of endothelial cells. J Am Acad Dermatol 49: 487-491.
25. Lehman TJ, Allen JB, Plotz PH & Wilder RL (1983) Polyarthritis in rats following the systemic injection of Lactobacillus casei cell walls in aqueous suspension. Arthritis Rheum 26: 1259-1265.
26. Lehman TJ, Warren R, Gietl D, Mahnovski V & Prescott M. (1988) Variable expression of Lactobacillus casei cell wall-induced coronary arteritis: an animal model of Kawasaki's disease in selected inbred mouse strains. Clin Immunol Immunopathol 48: 108-118.
27. Leung DY, Meissner HC, Fulton DR, Murray DL, Kotzin BL & Schlievert PM (1993) Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 342: 1385-1388.
28. Matsubara T, Furukawa S & Yabuta K (1990) Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon gamma in Kawasaki disease involved coronary artery lesions. Clin Immunol Immunopathol 56: 29-36.
29. Maury CPJ, Salo E & Pelkonen P (1988) Circulating interleukin-1 beta in patients with Kawasaki disease. N Engl J Med 319: 1670-1671.
30. Murata H (1979) Experimental candida-induced arteritis in mice. Relation to arteritis in the mucocutaneous lymph node syndrome. Microbiol Immunol 23: 825-831.
31. Nakamura T, Ueda Y, Juan Y, Katsuda S, Takahashi H & Koh E (2000) Fas-mediated apoptosis in adriamycin-induced cardiomyopathy in rats: in vivo study. Circulation 102: 572-578.
32. Nishimura S, Zaitsu M, Hara M, Yokota G, Watanabe M, Ueda Y, Imayoshi M, Ishii E, Tasaki H & Hamasaki Y (2003) A polymorphism in the promoter of the CD14 gene (CD14/- 159) is associated with the development of coronary artery lesions in patients with Kawasaki disease. J Pediatr 143: 357-362.
33. Ouchi K, Suzuki Y, Shirakawa T & Kishi F (2003) Polymorphism of SLC11A1 (formerly NRAMP1) gene confers susceptibility to Kawasaki disease. J Infect Dis 187: 326-329.
34. Ozaki S (2004) Molecular mechanism of vasculitis. Molecular Medicine. (Japanese) 41: 191-198.
35. Philip S, Lee WC, Liu SK, Wu MH & Lue HC (2004) A swine model of horse serum-induced coronary vasculitis: an implication for Kawasaki disease. Pediatr Res 55: 211-219.
36. Quasney MW, Bronstein DE, Cantor RM et al. (2001) Increased frequency of alleles associated with elevated tumor necrosis factor-alpha levels in children with Kawasaki disease. Pediatr Res 49: 686-690.
37. Rhee SG, Kang SW, Chang TS, Jeong W & Kim K (2001) Peroxiredoxin, a novel family of peroxidases. IUBMB Life 52: 35-41.
38. Sato N, Sagawa K, Sasaguri Y, Inoue O & Kato H (1993) Immunopathology and cytokine detection in the skin lesions of patients with Kawasaki disease. J Pediatr 122: 198-203.
39. Sireci G, Dieli F & Salerno A (2000) T cells recognize an immunodominant epitope of heat shock protein 65 in Kawasaki disease. Mol Med 6: 581-590.
40. Springer B, Master S, Sander P, Zahrt T, McFalone M, Song J, Papavinasasundaram KG, Colston MJ, Boettger E & Deretic V (2001) Silencing of oxidative stress response in Mycobacterium tuberculosis: expression patterns of ahpC in virulent and avirulent strains and effect of ahpC inactivation. Infect Immunol 69: 5967-5973.
41. Takeuchi K, Yamamoto K, Kataoka S, Kakihara T, Tanaka A, Sato S & Uchiyama M (1997) High incidence of angiotensin I converting enzyme genotype II in Kawasaki disease patients with coronary aneurysm. Eur J Pediatr 156: 266-268.
42. Ueno Y, Takano N, Kanegane H, Yokoi T, Yachie A, Miyawaki T & Taniguchi N (1989) The acute phase nature of interleukin 6 studies in Kawasaki disease and other febrile illnesses. Clin Exp Immunol 76: 337-342.
43. Wong M, Silverman ED & Fish EN (1997) Evidence for RANTES, monocyte chemotactic protein-1, and macrophage inflammatory protein-1 beta expression in Kawasaki disease. J Rheumatol 24: 1179-1185.
44. Yokota S, Minota S & Fujii N (2006) Anti-HSP auto-antibodies enhance HSP-induced pro-inflammatory cytokine production in human monocytic cells via Toll-like receptors. Int Immunol 18: 573-580.